SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : CardioDynamics (CDIC)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (170)5/21/2003 10:08:16 AM
From: tuck  Read Replies (1) of 201
 
>>SAN DIEGO--(BUSINESS WIRE)--May 21, 2003--CardioDynamics (Nasdaq:CDIC - News), the innovator and leader of Impedance Cardiography (ICG) technology and manufacturer of BioZ® noninvasive cardiac function monitoring systems, today announced the publication of an international clinical study demonstrating the significance of the company's ICG technology for pacemaker optimization in PACE, the foremost peer-reviewed publication in the field of electrophysiology.

The independent study, conducted by researchers at the Queen Mary Hospital (Hong Kong), University of Hong Kong, and St. Jude Medical, Sylmar, Calif., demonstrated the utility of the company's ICG technology to determine cardiac output (amount of blood the heart pumps each minute) during pacemaker optimization compared to the Echocardiography/Doppler (Echo) method. Although pacemaker optimization can significantly improve a patient's cardiac output, the vast majority of patients with dual chamber pacemakers are not optimized with Echo because it is a time-consuming, expensive and operator-dependent method. The study's investigators concluded, "Previous studies have shown that optimization of the AV (atrioventricular) interval can contribute up to 40% of the cardiac output. Therefore, it is an important step to maximize the hemodynamic benefits of cardiac pacing, especially during cardiac resynchronization therapy for congestive heart failure. This study demonstrates the feasibility and ease of use of the impedance technique to determine cardiac output during left ventricular pacing with close correlation with Doppler echo."

Michael K. Perry, Chief Executive Officer of CardioDynamics, stated, "This is an exciting application for our technology in a growing $3 billion pacemaker market. With each study and publication comes additional scientific support and invaluable exposure to the international medical community. With over 100 BioZ studies and 1.5 million patients monitored, we are building an industry that is contributing to reducing healthcare costs and improving patient care."

The company also announced it exhibited at the North American Society of Pacing and Electrophysiology (NASPE) 24th Annual Scientific Sessions held May 15-17, 2003, in Washington. The company updated and educated the cardiac pacing and electrophysiology physicians in attendance. There are 3,343 members of NASPE, 2,614 of who are from the U.S.<<

snip

The only abstract I can find that looks close is this one from January (CDIC not too helpful with keywords or authors for the PubMed search)

>>Pacing Clin Electrophysiol 2003 Jan;26(1 Pt 2):189-91

Impedance cardiography for atrioventricular interval optimization during permanent left ventricular pacing.

Tse HF, Yu C, Park E, Lau CP.

Division of Cardiology, Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China. hftse@hkucc.hku.hk

Left ventricular (LV) pacing is increasingly used in the management of congestive heart failure. Optimization of the atrioventricular (AV) interval is essential to maximize the hemodynamic benefits of this therapy. Although Doppler echocardiography (echo) is the most widely used method, it is time-consuming, expensive, and operator-dependent. We examined the value of an impedance cardiography (IC)-based method of cardiac output (CO) measurement to optimize the AV interval in 5 men and 1 woman (mean age = 72 +/- 11 years) during permanent LV pacing with a 4.8 Fr unipolar coronary sinus pacing lead. Simultaneous measurements of CO by IC and echo were performed at AV intervals of 50, 80, 110, 150, 180, and 225 ms during DDD pacing at 85 beats/min. The optimal AV interval varied between 110 and 180 ms. In 5 of 6 patients (83%), the optimal AV interval by echo and IC was identical. While CO measurements were higher with IC than with echo (6.1 +/- 0.4 L/min vs 4.7 +/- 0.3 L/min, P < 0.05), CO measurements by IC and echo were closely correlated r = 0.67, P < 0.001). In conclusion, our initial experience suggests that IC is a reliable method of AV interval optimization during LV pacing. IC and echo measurements of CO during LV pacing were closely correlated.<<

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext